Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIMD Ainos	$0.50 +3.7%	$0.55	$0.40 ▼ $1.07	$10.48M	2.2	245,292 shs	258,441 shs
KZR Kezar Life Sciences	$4.44 +4.0%	$4.30	$3.62 ▼ $9.18	$32.46M	0.58	52,479 shs	46,562 shs
OSTX OS Therapies	$1.84 +1.7%	$1.76	$1.12 ▼ $7.00	$51.70M	N/A	458,059 shs	254,659 shs
SRZN Surrozen	$9.02 +8.0%	$8.89	$5.90 ▼ $18.17	$77.21M	0.58	22,083 shs	23,827 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIMD Ainos	0.00%	-1.07%	-25.90%	+1.79%	-38.54%
KZR Kezar Life Sciences	0.00%	-1.77%	+6.47%	-9.02%	-26.00%
OSTX OS Therapies	0.00%	+3.37%	+20.26%	+19.48%	+183,999,900.00%
SRZN Surrozen	0.00%	-9.71%	+6.12%	-22.64%	-17.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIMD Ainos	0.9191 of 5 stars	0.0	4.0	0.0	1.4	1.7	0.6
KZR Kezar Life Sciences	4.2798 of 5 stars	3.2	3.0	4.6	3.3	1.7	0.6
OSTX OS Therapies	2.3657 of 5 stars	3.7	0.0	0.0	1.8	1.7	0.6
SRZN Surrozen	3.1723 of 5 stars	3.5	3.0	0.0	3.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIMD Ainos	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$39.50	789.64% Upside
OSTX OS Therapies	3.40	Buy	$18.00	878.26% Upside
SRZN Surrozen	3.00	Buy	$38.50	326.83% Upside

Current Analyst Ratings Breakdown

Latest AIMD, OSTX, KZR, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/12/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/7/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/2/2025	OSTX OS Therapies	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
4/2/2025	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
3/31/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIMD Ainos	$20K	524.00	N/A	N/A	$1.10 per share	0.45
KZR Kezar Life Sciences	$7M	4.64	N/A	N/A	$16.02 per share	0.28
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	$10.65M	7.25	N/A	N/A	($6.55) per share	-1.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIMD Ainos	-$14.86M	-$1.29	N/A	∞	N/A	N/A	-88.07%	-48.60%	8/4/2025 (Estimated)
KZR Kezar Life Sciences	-$83.74M	-$10.82	N/A	N/A	N/A	N/A	-61.15%	-50.27%	8/12/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
SRZN Surrozen	-$63.56M	-$24.96	N/A	N/A	N/A	N/A	-842.90%	-71.32%	8/11/2025 (Estimated)

Latest AIMD, OSTX, KZR, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	-$2.27	+$0.29	-$2.27	N/A	N/A
5/12/2025	Q1 2025	AIMD Ainos	N/A	-$0.21	N/A	-$0.21	N/A	$0.11 million
5/9/2025	Q1 2025	SRZN Surrozen	-$1.09	-$3.13	-$2.04	-$7.43	N/A	$0.98 million
3/31/2025	Q4 2024	SRZN Surrozen	-$2.54	-$9.10	-$6.56	-$9.10	N/A	$0.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIMD Ainos	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIMD Ainos	0.84	2.00	1.91
KZR Kezar Life Sciences	0.04	7.09	7.09
OSTX OS Therapies	N/A	0.76	0.76
SRZN Surrozen	N/A	10.02	10.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIMD Ainos	N/A
KZR Kezar Life Sciences	67.90%
OSTX OS Therapies	N/A
SRZN Surrozen	66.57%

Insider Ownership

Company	Insider Ownership
AIMD Ainos	10.39%
KZR Kezar Life Sciences	9.30%
OSTX OS Therapies	13.80%
SRZN Surrozen	43.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIMD Ainos	40	20.96 million	18.78 million	Not Optionable
KZR Kezar Life Sciences	60	7.31 million	6.63 million	Not Optionable
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
SRZN Surrozen	80	8.56 million	4.84 million	Not Optionable

AIMD, OSTX, KZR, and SRZN Headlines

Recent News About These Companies

Surrozen (NASDAQ:SRZN) Shares Down 1.4% - What's Next?

June 25, 2025 | marketbeat.com

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 16.0% in May

June 3, 2025 | marketbeat.com

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround

May 16, 2025 | zacks.com

Surrozen secures patent for tissue repair technology

May 15, 2025 | investing.com

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 14, 2025 | globenewswire.com

Surrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 10, 2025 | finanznachrichten.de

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025 | globenewswire.com

Surrozen files to sell 5.21M shares of common stock for holders

April 25, 2025 | markets.businessinsider.com

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

April 2, 2025 | markets.businessinsider.com

Insiders Are Loving These 5 Tech and Biotech Stocks

April 2, 2025 | 247wallst.com

Surrozen Focuses on Ophthalmology Amid Financial Challenges

April 1, 2025 | tipranks.com

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

March 31, 2025 | globenewswire.com

Surrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 Shares

March 29, 2025 | insidertrades.com

Surrozen to focus Wnt expertise, technologies on ophthalmology programs

March 27, 2025 | markets.businessinsider.com

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

March 26, 2025 | markets.businessinsider.com

Surrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 Development

March 24, 2025 | quiverquant.comQ

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

March 24, 2025 | globenewswire.com

Surrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News Summary

January 30, 2025 | benzinga.com

HC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy Recommendation

January 30, 2025 | msn.com

H.C. Wainwright sets $32 target on Surrozen stock with Buy rating

January 30, 2025 | msn.com

(SRZN) Trading Advice

January 30, 2025 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIMD, OSTX, KZR, and SRZN Company Descriptions

Ainos NASDAQ:AIMD

$0.50 +0.02 (+3.69%)

As of 06/27/2025 04:00 PM Eastern

Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.

Kezar Life Sciences NASDAQ:KZR

$4.44 +0.17 (+3.98%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.28 -0.16 (-3.60%)

As of 04:05 AM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

OS Therapies NYSE:OSTX

$1.84 +0.03 (+1.66%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.89 +0.05 (+2.72%)

As of 05:21 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Surrozen NASDAQ:SRZN

$9.02 +0.67 (+8.02%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.00 -0.02 (-0.22%)

As of 06/27/2025 05:38 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time